Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | ALPL | P05186 | 3/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570129 | 0.88 | MCHR1 (0.53) | MCHR1GAA | |
| SCHEMBL569406 | 0.85 | LCLAT1 (0.44) | MCHR1MAPTHTTSMN1; SMN2 | |
| SCHEMBL569755 | 0.84 | KDM4E (0.46) | HDAC1MCHR1P2RY14MAPT | |
| SCHEMBL570766 | 0.82 | EPHA2 (0.44) | HDAC1HDAC2MCHR1GAAMAPT | |
| SCHEMBL569170 | 0.80 | HDAC3 (0.48) | HDAC1HDAC2MCHR1GAALRRK2 | |
| SCHEMBL570223 | 0.80 | CHRNB4 (0.42) | MCHR1GAALRRK2CHRNB4CHRNA3 | |
| SCHEMBL570140 | 0.79 | TBK1 (0.43) | MCHR1TBK1GAAMAPTSMN1; SMN2 | |
| SCHEMBL570141 | 0.79 | MCHR1 (0.41) | MCHR1GAAMAPTSMN1; SMN2 | |
| SCHEMBL10182402 | 0.77 | CHRNB4 (0.39) | MCHR1GAALRRK2CHRNB4CHRNA3 | |
| SCHEMBL10182704 | 0.75 | CHRNB4 (0.39) | MCHR1GAALRRK2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| EP-2601208-B1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| EP-2601208-B1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| EP-2601208-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | Graffinity Pharmaceuticals GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| WO-2012017021-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017021-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCGR3B | HDAC1 2633/4885HDAC2 3234/4885MCHR1 2675/4885 |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCER2 | HDAC1 161/4885HDAC2 327/4885MCHR1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.